Introduction
The most prevalent kind of leishmaniasis is cutaneous leishmaniasis. It is brought on by more than 15 distinct species of the protozoan parasite Leishmania, which is spread by female sandflies that transmit the infection. Cutaneous leishmaniasis is not fatal, but it can have a terrible impact on populations close by. It results in deformative skin lesions, particularly in women and children, and can inflict lifelong scars and extreme social shame. Economic loss, less education, and social exclusion are among the effects. These impacts are particularly severe since cutaneous leishmaniasis mostly affects those with poor resources. Mucocutaneous leishmaniasis can develop after months or even years once the skin ulcers heal and manifest as a consequence of cutaneous leishmaniasis. Damage to the mucosal membranes of the mouth, throat, and nose, as well as the surrounding tissues, can result in lesions that cause partial or complete destruction. This can cause disability and social stigma. Mucocutaneous leishmaniasis, in contrast to the majority of cutaneous leishmaniasis, is unlikely to cure on its own; in situations of severe mucocutaneous leishmaniasis, individuals may not survive without treatment.
What Are the Symptoms of Cutaneous Leishmaniasis?
Clinical manifestations of cutaneous leishmaniasis can vary greatly; there might be simple, self-healing skin lesions, debilitating, massive, chronic, or recurrent lesions, disfiguring mucosal or mucocutaneous lesions in the mouth or nose, or widespread cutaneous leishmaniasis. Depending on the disease's form and intensity, cutaneous leishmaniasis can cause extreme social stigma and, in certain situations, permanent disability. Small bumps turn into open lesions with a raised border and a center crater, or ulcer, that can be covered with scabs, as the sores progress. Although normally harmless, the lesions can cause discomfort, especially if open sores are infected with pathogens.
What Causes Cutaneous Leishmaniasis?
Leishmaniasis is caused by leishmania parasites. They are found in humans as well as animals such as foxes, dogs, cats, possums, and rodents. Leishmaniasis is transmitted through the bite of the phlebotomine sand fly. After biting an infected human or animal, the sand fly injects the parasite Leishmania into another bite victim. Less frequently, one can contract leishmania by:
-
Distributing needles.
-
By the transfusion of blood.
-
From the fetus to the pregnant person.
People's risk of infection is influenced by several factors, such as migration, climate change, starvation, unsanitary household situations, and inadequate housing.
Who Does Cutaneous Leishmaniasis Affect?
The majority of Cutaneous leishmaniasis cases occur in rural tropical settings or places with poor sanitation. Individuals with HIV and other immune-suppressive disorders are more susceptible to contracting a cutaneous leishmaniasis infection. It might be challenging to determine the prevalence of cutaneous leishmaniasis since many individuals can get the disease without exhibiting any symptoms. An estimated one million five hundred thousand to two million individuals globally have symptoms each year, according to experts.
More than 90 nations worldwide have leishmania. There are several forms of Leishmania in different regions of the world. Depending on the location, experts refer to leishmaniasis as either "Old World leishmaniasis" or "New World leishmaniasis."
The Eastern Hemisphere is home to Old World leishmaniasis, which includes several regions of Asia and parts of Africa, notably the continent's tropical zones and North Africa, Europe's south.
The Eastern Mediterranean, The Western Hemisphere is home to cases of New World leishmaniasis, which includes Central America, South America, and certain regions of Mexico.
How Is Cutaneous Leishmaniasis Diagnosed?
Leishmania is detected in tissue samples taken from different areas of the body to diagnose leishmaniasis. These samples might be bone marrow, spleen, lymph nodes, or ulcer tissue. Healthcare professionals frequently depend on symptom evaluation or visual inspection of the skin for diagnosis in areas where leishmaniasis is common.
-
Skin Biopsies: These diagnostic procedures for leishmaniasis entail taking a sample of tissue from a lesion on the mouth, nose, or skin. The diagnosis of cutaneous or mucosal leishmaniasis is aided by laboratory examination of the tissue sample.
-
Hematologic Tests: Healthcare professionals may occasionally look for signs of a Leishmania infection in the blood. Either a tiny needle is put into a vein to draw blood, or the skin is punctured with a needle.
What Are the Treatment Options for Cutaneous Leishmaniasis?
-
There are significant challenges associated with the safety, accessibility, and resistance of currently available drugs for treating certain conditions.
-
The medications in question pose difficulties in administration, requiring prolonged use and often resulting in poor tolerance by patients.
-
Examples include meglumine antimoniate and sodium stibogluconate, both belonging to the category of pentavalent antimony.
-
Treatment involves enduring a 21-day course at a hospital or clinic, where patients undergo painful intramuscular injections one to two times a week for three to seven weeks.
-
The effectiveness of these drugs can be as low as fifty percent in certain regions, raising concerns about their overall impact.
-
Furthermore, these medications come with significant drawbacks, including a high risk of fatal cardiotoxicity.
-
They are also found to be less effective in younger children under the age of five.
-
Additionally, the financial burden of the lengthy and challenging treatment process can be overwhelming for households.
-
The costliness of the drugs, coupled with the difficulty for individuals attending hospitals or clinics daily to receive treatment, creates barriers to access. As a result, people, especially those from rural areas, and caregivers of sick children may be deterred from seeking treatment or may discontinue it prematurely due to the associated hardships and financial strain.
-
Miltefosine represents a treatment option for certain conditions, administered orally over 28 days with twice-daily doses. However, its effectiveness is hindered by challenges such as low adherence among patients, primarily due to the drug's side effects and the extended duration of the treatment. Notably, the medication is contraindicated during pregnancy, adding a layer of complexity to its usage.
-
The emergence of resistance to miltefosine poses a concerning issue, further limiting its efficacy.
-
Moreover, the accessibility of miltefosine is restricted as it is not available in many countries.
-
This limited availability contributes to the obstacles in providing comprehensive healthcare for individuals in need.
-
Additionally, for women capable of bearing children, the drug requires cautious consideration, as it cannot be used during pregnancy or without adequate contraception measures.
-
These various factors underscore the challenges associated with miltefosine, ranging from issues related to adherence, contraindications, resistance, and global accessibility.
What Are the New Treatment Options for Cutaneous Leishmaniasis?
Patients require a safe therapy option that they may take orally or apply topically. An effective therapy should be inexpensive, well-tolerated, and able to quickly heal wounds without leaving noticeable scars. It should also be appropriate for use in clinic settings, enabling self-management without requiring professional follow-up. When challenges occur, the use of immunomodulators may improve the efficacy of antiparasitic medications.
Conclusion
Treatments for cutaneous leishmaniasis must be easily available, bearable, and affordable, and they must leave the least amount of scarring possible. Innovations that facilitate clinic self-administration are essential. Promising research is being done on immunomodulators for complex cases, which should provide all-encompassing treatments for this parasite skin disease.
